Affiliation:
1. Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
Abstract
ABSTRACT
Introduction Depression is responsible for 800 000 deaths
worldwide, a number that will rise significantly due to the COVID-19
pandemic. Affordable novel drugs with less severe side effects are urgently
required. We investigated the effect of withanone (WN) from Withania
somnifera on the serotonin system of wild-type and knockout Caenorhabditis
elegans strains using in silico, in vitro, and in vivo methods.
Methods WN or fluoxetine (as positive control drug) was administered
to wild-type (N2) and knockout C. elegans strains (AQ866, DA1814, DA2100,
DA2109, and MT9772) to determine their effect on oxidative stress (Trolox,
H2DCFDA, and juglone assays) on osmotic stress and heat
stress and lifespan. Quantitative real-time RT-PCR was applied to
investigate the effect of WN or fluoxetine on the expression of serotonin
receptors (ser-1, ser-4, ser-7) and serotonin transporter
(mod-5). The binding affinity of WN to serotonin receptors and
transporter was analyzed in silico using AutoDock 4.2.6.
Results WN scavenged ROS in wild-type and knockout C. elegans and
prolonged their lifespan. WN upregulated the expression of serotonin
receptor and transporter genes. In silico analyses revealed high binding
affinities of WN to Ser-1, Ser-4, Ser-7, and Mod-5.
Limitations Further studies are needed to prove whether the results
from C. elegans are transferrable to mammals and human beings.
Conclusion WN ameliorated depressive-associated stress symptoms by
activating the serotonin system. WN may serve as potential candidate in
developing new drugs to treat depression.
Subject
Pharmacology (medical),Psychiatry and Mental health,General Medicine
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献